/index.php?option=com_iwpfile&file=/dir_01/he2002_1316.pdf


on

Letter

March 19, 2002

The Honorable Kent Conrad

Chairman

Senate Budget Committee

602 Dirksen Senate Office Building

Washington, D.C. 20510

The Honorable Pete Domenici

Ranking Member

Senate Budget Committee

634 Dirksen Senate Office Building

Washington, D.C. 20510

Dear Senator Conrad and Senator Domenici:



For Release: Immediately

Contact: AHRQ Public Affairs (301) 594-1364

Karen J. Migdail (301) 594-6120

Headline: SECRETARY THOMPSON NAMES CAROLYN CLANCY, M.D., AS ACTING DIRECTOR OF AHRQ

HHS Secretary Tommy G. Thompson today appointed Carolyn Clancy, M.D., as acting director of the Agency for Healthcare Research and Quality (AHRQ), succeeding John M. Eisenberg, M.D., who passed away March 10.



/index.php?option=com_iwpfile&file=/dir_01/he2002_1312.pdf


ep

Tauzin Statement on President's Medical Privacy Proposal

WASHINGTON (March 22) - Responding to the Bush Administration's proposed changes to the medical privacy rule, House Energy and Commerce Committee Chairman Billy Tauzin (R-LA) today issued the following statement:

"I applaud the Administration's efforts to address some of the serious concerns that were raised with the final privacy rule issued late last year by the outgoing Clinton Administration.



es

Statement by John J. Sweeney On the One Year Anniversary of the Repeal of the OSHA Ergonomics Standard

March 20, 2002

One year ago today, in his first major legislative action, President Bush repealed the Occupational Safety and Health Administration's standard. The President undid a rule that was 10 years in the making and protected workers from some of the most pervasive workplace health and safety hazards today.



/index.php?option=com_iwpfile&file=/dir_01/he2002_1308.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_1309.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_1310.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_1307.pdf


Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.